Research programme: anticancer therapeutics - Medpacto
Alternative Names: TEW 0201; UAI 201Latest Information Update: 25 Apr 2023
At a glance
- Originator YOUAI
- Developer MedPacto
- Class Small molecules; Sulfonamides
- Mechanism of Action Proto-oncogene protein b-raf inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Colorectal cancer; Malignant melanoma
- Discontinued Cancer
Most Recent Events
- 25 Apr 2023 Discontinued - Preclinical for Cancer in South Korea (unspecified route) (MedPacto pipeline,
- 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in South Korea
- 04 Nov 2017 No recent reports of development identified for preclinical development in Colorectal-cancer in South Korea